TM4 of the glutamate transporter GLT-1 experiences substrate-induced motion during the transport cycle

Xiuliang Rong1,2,3,*, Feng Tan4,*, Xiaojuan Wu1,2, Xiuping Zhang6, Lingli Lu1,2, Xiaoming Zou6 & Shaogang Qu1,2

Excitatory amino acid transporter 2 (EAAT2), also known as glial glutamate transporter type 1 (GLT-1), plays an important role in maintaining the extracellular glutamate concentrations below neurotoxic levels. The highly conserved TM2 transmembrane domain of GLT-1 maintains a stable position during the transport cycle; however, the effect of the transport cycle on the topology of TM4 is not well established. To further reveal the function of TM4, two cysteine pairs between TM2 and TM4 were introduced using site-directed mutagenesis. A significant decrease of transport activity was observed in the I93C/V241C and I97C/V241C mutants upon application of the oxidative cross-linking reagent, copper (II) (1,10-phenanthroline), (CuPh), which suggests that a conformational shift is essential for transporter activity. Furthermore, the decrease in activity by CuPh crosslinking was enhanced in external media with glutamate or potassium, which suggests that TM2 and TM4 assume closer proximity in the inward-facing conformation of the transporter. Our results suggest that the TM4 domain of GLT-1, and potentially other glutamate transporters, undergoes a complex conformational shift during substrate translocation, which involves an increase in the proximity of the TM2 and TM4 domains in the inward-facing conformation.

Glutamate is the most important excitatory neurotransmitter in the central nervous system. It must be immediately removed after it has been released into the synaptic cleft and transmitted a nerve impulse. Glutamate transporters, also referred to as excitatory amino acid transporters (EAATs), are responsible for the recycling of glutamate in the synaptic cleft, thus maintaining the external concentration of glutamate below neurotoxic levels and ensuring the precise control of excitatory synaptic transmission. Five mammalian subtypes of EAATs have been characterized so far: EAAT1–EAAT51–6. The members of the glutamate transporter family, which include the EAATs, as well as prokaryotic transporters and two Na+/dependent neutral amino acid transporters, are about 25 to 30% identical7. This homology results in a similar membrane topology and transport mechanism for all family members8–20. The EAATs drive glutamate uptake by the cotransport of three sodium ions and one proton and the countertransport of one potassium ion21. The transport of the substrate against the concentration gradient by EAATs also uses energy, and this energy is generated indirectly by the Na+/K+-ATPase pathway22.

The crystal structures of prokaryotic aspartate transporter homologues in different states have been resolved9,16,20,23–25. The experimentally determined membrane topology of the glutamate transporter EAAT2 (also known as glial glutamate transporter type 1, GLT-1) is supported by the crystal structure of a homolog...
of eukaryotic glutamate transporters, GltPh1,12,13,18,20. The first resolved crystal structure of GltPh revealed a bowl-shaped homotrimer with three identical monomers20. Every monomer functions as an independent unit with an individual substrate-binding site. Each monomer can be subdivided into two parts: the transporter core and the transporter cylinder. The transporter core contains the substrate and ion binding sites and is comprised of two reentrant helical hairpin loops (HP1 and HP2) and transmembrane (TM) segments 7 and 8. HP1 is speculated to form the internal gate of the transporter, while HP2 forms the external gate9,10,16,17,20,26. The transporter cylinder, which surrounds the transporter core, and maintains balance during the transport cycle, is comprised of TM1 through TM69,16,20.

Previous experiments to characterize the spatial relationships between the tip of HP1 or HP2 and TM4 have suggested that TM4 may undergo a complex conformational shift during the transport cycle27. However, TM2, which is highly conserved among GltPh and other transporter subtypes, is thought to maintain the balance of the transporter during the translocation of the transporter core20. Therefore, we speculated that we might obtain additional information about the conformational shift in TM4 during the transport cycle by investigating the effects of crosslinking TM4 to TM2. We introduced cysteine pairs into TM2 and TM4 of GLT-1 and examined the effects of the oxidative cross-linking reagent, copper (II) (1,10-phenanthroline)3 (CuPh) on transport activity. We also examined whether application of glutamate and potassium might have additional effect on the transport activity of the mutants. Moreover, we examined the aqueous accessibility of single cysteine mutants in various external media using the membrane-impermeable sulfhydryl reagent (2-trimethylammonium) methanethiosulphonate (MTSET). Our data suggest that there is a complex relative motion between TM2 and TM4 and that a conformational shift of TM4 may occur during substrate transport cycle.

Results
Inhibition of transport of cysteine mutants by CuPh. To determine the function of the TM4 domain of GLT-1, we constructed three double mutants for reversible cross-linking of the TM2 and TM4 domains, which are thought to lie in close proximity to each other. The Ile-93, Ile-97, or Leu-94 residues within the TM2 domain of cysteine-less GLT-1 (CL-GLT-1), together with the Val-241 residue within the TM4 domain, were mutated to cysteines to create I93C, I93C/V241C, and I97C/V241C double mutants. While the molecular structure of GLT-1 has not been determined, structural models for GltPh, which is in the same family of transporters, show that it can assume substrate-binding, outward-facing or inward-facing conformations (Fig. 1A–C). The three structures are viewed from the outside with dashed lines indicating the distances between the Cα-atoms (rose spheres) of the indicated residues. Val-58, Val-62, and Val-151 are equivalent to Ile-93, Ile-97, and Val-241 of CL-GLT-1, respectively. (D) Comparison of the amino acid sequences of TM4 between GltPh and EAATs. Regions of high homology of GltPh and EAATs are highlighted in blue. The alignment of V151 of GltPh and V241 of GLT1 is highlighted in yellow. The 4b,4c loop is present only in the EAAT transporters.

Figure 1. Membrane topology model of GLT-1/EAAT2. A schematic diagram is shown of the relative locations of Val-58, Val-62, and Val-151 of GltPh on TM2 (dark blue) and TM4 (green) in the substrate-binding (A) PDB ID: 1XFH), outward-facing (B) PDB ID: 2NWW) and inward-facing (C) PDB ID: 3KBC) structures. The three structures are viewed from the outside with dashed lines indicating the distances between the Cα-atoms (rose spheres) of the indicated residues. Val-58, Val-62, and Val-151 are equivalent to Ile-93, Ile-97, and Val-241 of CL-GLT-1, respectively. (D) Comparison of the amino acid sequences of TM4 between GltPh and EAATs. Regions of high homology of GltPh and EAATs are highlighted in blue. The alignment of V151 of GltPh and V241 of GLT1 is highlighted in yellow. The 4b,4c loop is present only in the EAAT transporters.
addition, comparing with CL-GLT-1, there was no difference for the ratio of the biotinylated signal and the non-biotinylated signal of each mutant, which indicated that the trafficking of the mutants to the plasma membrane are normal (Fig. 2E). We elected to compare transport activities with and without CuPh as an internal control for the individual activity of each protein. On the other hand, L94C/V241C showed more radically impaired substrate transport in the absence of CuPh (only 8.3±2.3% activity), and consequently L94C/V241C was not used for further testing.

Further examination of I93C/V241C and I97C/V241C demonstrated that substrate uptake was decreased by CuPh in a dose-dependent manner, though the transport activity of CL-GLT-1 was not significantly inhibited at a range of CuPh doses (Fig. 3A). This inhibition of transport activity of the double mutants may be due to the formation of a disulfide bond between the two introduced cysteines that blocks the conformational shift of the transporter.14,28,29 About 50% inhibition of transport activity was observed at 50 μM for I93C/V241C and I97C/V241C while about 80% inhibition of transport activity was observed at 300 μM. Moreover, despite the significant inhibition of the double mutant, 300 μM CuPh did not cause inhibition in cells expressing single mutants that were either transfected individually or were co-transfected (Fig. 3B). These data indicate that the formation of a disulfide bond between two introduced cysteines within the same monomer is essential for CuPh-dependent inhibition.

The maximum transport rate (V_{max}) and the apparent transport affinity (K_{m}) of substrate were measured with or without pretreatment of CuPh to determine whether cross-linking changes the kinetic parameters. As shown in Table 1, both I93C/V241C and I97C/V241C showed a lower V_{max} in the presence of CuPh. This indicates that
the oxidative cross-linking between I93C and V241C or I97C and V241C damages transport function. In the absence of CuPh the 
\( K_m \) values of all of the mutants were comparable to that of CL-GLT-1; however, incubation of the I93C/V241C and I97C/V241C double mutants with CuPh caused a clear elevation in the 
\( K_m \) values of these double mutants, while the corresponding individual mutants showed no change. These results indicate that the formation of disulfide-bonds between TM2 and TM4 specifically impairs the substrate-binding ability of the GLT-1 transporter.

The restorative effect of DTT on the CuPh-mediated inhibition of the transport activity of double mutants. In rare cases, the formation of a covalent bond can occur between a sulphydryl and another chemical group in the presence of CuPh. To rule out this possibility and to further verify the specificity of the inhibition by CuPh, we used the reducing agent dithiothreitol (DTT) to reverse the formation of the dicysteine sulphydryl bond. Consistent with the above findings, the transport activities of I93C/V241C and I97C/V241C were inhibited to 21.2 \( \pm \) 2.9% and 22.2 \( \pm \) 2.0% by the application with 300 \( \mu \)M CuPh; however, simultaneous treatment with 20 mM DTT restored the transport activities of the double mutants to 68.0 \( \pm \) 2.1% and 72.1 \( \pm \) 1.3% (Fig. 4A,B). By comparison, DTT had no significant effect on the activity of CL-GLT1 (data not shown). These findings further confirm that CuPh induces the formation of the covalent bonds between the two cysteines that were introduced into the double mutants.

### Table 1. Kinetic parameters of transporter mutants in the absence or presence of CuPh.

|       | \( V_{\text{max}} \) | \( K_m \) | CuPh |
|-------|---------------------|-----------|------|
|       | \( \mu \)M          | \( \mu \)M | \( \mu \)M |
| CL-GLT-1 | 100               | 31.3 \( \pm \) 4.6 | 98.4 \( \pm \) 1.2 | 30.7 \( \pm \) 3.5 |
| I93C/V241C | 16.4 \( \pm \) 1.2 | 29.2 \( \pm \) 2.5 | 7.5 \( \pm \) 1.3* | 57.6 \( \pm \) 2.7* |
| I97C/V241C | 25.2 \( \pm \) 2.3 | 34.1 \( \pm \) 2.8 | 10.7 \( \pm \) 1.6* | 56.3 \( \pm \) 2.4* |
| I93C     | 21.8 \( \pm \) 2.6 | 29.8 \( \pm \) 3.1 | 20.3 \( \pm \) 2.2 | 31.1 \( \pm \) 2.8 |
| I97C     | 39.3 \( \pm \) 2.1 | 30.6 \( \pm \) 2.9 | 37.1 \( \pm \) 2.5 | 29.5 \( \pm \) 1.7 |
| V241C    | 45.6 \( \pm \) 3.4 | 28.3 \( \pm \) 1.8 | 42.5 \( \pm \) 1.6 | 30.6 \( \pm \) 2.1 |

Values that were significantly different in the absence and presence of CuPh, as determined by the Student t-test, are indicated (* \( P < 0.05 \)).

**Figure 3. Inhibition of transport of cysteine mutants by CuPh.** (A) Dose-response effect of CuPh on D-[\( ^{3} \)H]-Asp transport activity of CL-GLT-1, I93C/V241C and I97C/V241C. (B) Inhibition of transport by 300 \( \mu \)M CuPh is also shown for I93C/V241C and I97C/V241C double mutants, as well as for transporter proteins harboring corresponding individual mutants. The bars marked “I93C co V241C” and “I97C co V241C” represent individual mutants that were co-transfected. In each case, cells expressing mutants and CL-GLT-1 were treated with CuPh in NaCl solution for 5 min before the transport assay. Data represent the percentages of the remaining uptake activity of samples relative to those without any CuPh treatment (mean \( \pm \) S.E., \( n = 3 \)). Values that are significantly different from those of CL-GLT-1 were determined by one-way ANOVA (* \( P < 0.05 \); ** \( P < 0.01 \)).
Inhibition of transport of cysteine mutants by cadmium. To verify that the two mutations for each of the double mutants are closely positioned within the GLT-1 protein, we assessed the effects of cadmium (Cd\(^{2+}\)), which is known to bind the side chains of two coordinated cysteines with high affinity\(^{29,30}\). Substrate uptake was decreased after exposure to 500 \(\mu\)M Cd\(^{2+}\) for both I93C/V241C (7.3 ± 2.3% of control) and I97C/V241C (13.3 ± 2.8% of control). In contrast, cells expressing single mutants alone or in combination were not significantly affected by 500 \(\mu\)M Cd\(^{2+}\) (Fig. 5A,B). These data support the intramolecular spatial proximity of Ile-93 and Ile-97 in TM2 to Val-241 in TM4.

Effect of external media on the CuPh-mediated inhibition of the transport activity of double mutants. To determine the influence of various external media on the oxidative inhibitory effect of cross-linking TM2 and TM4, the substrate uptakes of I93C/V241C and I97C/V241C were measured after incubation for 5 min with 50 \(\mu\)M CuPh. This concentration induces half-maximal inhibition in NaCl (Fig. 3A). When the external sodium was substituted with potassium or supplemented with glutamate, each of which increases the proportion of inward-facing transporter\(^{16,31}\), CuPh on I93C/V241C and I97C/V241C caused more notable inhibition (Fig. 6A,B, first three bars). This suggests that cross-linking of TM2 to TM4 is more detrimental for proteins that are in an inward-facing conformation. As a control, this enhanced inhibition was not observed when sodium was replaced by choline or lithium (Fig. 6A,B, fourth and fifth bars). Additionally, when the external sodium was
supplemented with the non-transportable substrate analogue TBOA, which increases the proportion of transporters in the outward-facing conformation, the inhibitory effects of CuPh on I93C/V241C and I97C/V241C were not significantly changed (Fig. 6A, B, last bar). These results suggest that the inhibitory effects of cross-linking TM2 and TM4 are increased for inward-facing transporters, but not for outward-facing transporters.

Effect of external media on the inhibition of transport activity by MTSET in single mutants.

There are two potential explanations for why the inhibitory effect by CuPh on transporter activity might differ according to the external media that is used. First, the enhanced effects of CuPh for the inward facing conformation could potentially be explained by a smaller spatial distance between I93 or I97 and V241. This possibility would suggest a divergence from the structural model for GltPh and could potentially be explained by the 53 additional amino acids present in the TM4 domain of GLT-1 (Fig. 1). Our findings are consistent with this possibility.

A second, less likely possibility is that the change in conformation of the transporter protein could affect the aqueous accessibility of CuPh to an individual cysteine residue. To rule out the latter possibility, the accessibility of each individual site was assessed using the membrane-impermeable sulfhydryl reagent MTSET. Our results demonstrate that the transport activity of a V241C single mutant decreased gradually with increased MTSET concentration; however, I93C and I97C were not sensitive to MTSET (Fig. 7A), either in NaCl media or in various other external media (Fig. 7B, C). After treatment with 0.5 mM MTSET, the transport activity of V241C was inhibited to about 40%, which is consistent with its aqueous accessibility within TM4. Furthermore, glutamate and external potassium partially reversed the MTSET-mediated inhibition of substrate uptake by V241C. A similar
protection was also detected when external sodium was supplemented with TBOA (Fig. 7D). These results indicate that the change in accessibility of V241C is complex and cannot directly explain the increased CuPh inhibition of the I93C/V241C and I97C/V241C double mutants.

**Discussion**

As the main transporters for clearing glutamate in the synaptic cleft, EAATs have been reported to be involved in the pathogenesis of various neurodegenerative diseases. Therefore, further research into the transport mechanism of EAATs is urgent. Though the EAATs are highly conserved and are similar in structure to GltPh, there are 53 more amino acid residues of TM4 in GLT-1 than in GltPh (Fig. 1D). The differences in the number of amino acids between the TM4 of EAATs and GltPh may lead to some differences in their spatial conformations and transport mechanisms. Previous research investigating the spatial relationships between HP1 and TM4 or HP2 and TM4 suggests that TM4 may undergo a complex conformational shift during the transport cycle. The aim of this work was to re-examine the conformational shift of TM4 during the substrate transport cycle in EAATs by investigating the proximity of residues in TM2 and TM4 in GLT-1.

We determined that CuPh can inhibit the transport activity of both I93C/V241C and I97C/V241C double cysteine mutants (Fig. 3), but that the addition of 20 mM DTT can reverse this effect (Fig. 4). Similar inhibition of transport activity was observed using Cd2+ (Fig. 5). We speculate that a disulfide bond between I93C/V241C or I97C/V241C forms upon incubation with CuPh or Cd2+ because of the close proximity between the residues...
Ile-93 and Val-241 or Ile-97 and Val-241. The formation of a disulfide bond would be presumed to lock the conformation of the transporter, which would obstruct further conformational shifts during the transport cycle. In the native molecule, the conformation of the transporter constantly changes during the substrate transport cycle. Our findings suggest that conformational lock leads to a decrease in transport activity.

We further examined the effects of conformational lock on transporters that were converted into predominant inward- or outward-facing conformation. The addition of the substrate glutamate or the replacement of sodium with potassium causes an increase in the percentage of inward-facing transporters. Conversely, the substrate inhibitor TBOA increases the percentage of outward-facing transporters. Therefore, we were able to observe the effects of CuPh cross-linking on different transporter conformations by modifying the medium outside of the cell. Our results show that the inhibitory activity of CuPh was further increased when the mutant transporters were converted to inward-facing conformations with either glutamate or potassium (Fig. 6). These data indicate that the distances between Ile-93 and Val-241 or Ile-97 and Val-241 had no obvious change when the transporter was trapped in the outward-facing state. Short-lived conformations could potentially result in cross-linking, and we therefore examined cross-linking for different conformations, including the substrate-binding, outward-facing and inward-facing structures. The results show that cross-linking can form at these three conformations, but that the decrease in activity by CuPh cross-linking was most severe at the inward-facing conformation. Therefore, it is likely the inward-facing conformation represents...
a naturally-occurring structure. These findings suggest a divergence from the findings for GltPh. According to the crystallographic structure of GltPh, the Cα-Cα distances of Val-58/Val-62 and Val-151, which are equivalent to Ile-93/Ile-97 and Val-241 of CL-GLT-1, are similar in the substrate-binding, outward-facing and inward-facing structures (8.3, 8.9 and 9.6 Å for Val-58 to Val-151; 7.5, 7.8 and 8.0 Å for Val-62 to Val-151; Fig. 1A–C). The TM4 domains of both GltPh and EAATs contain three separated α-helices: TM4a, TM4b and TM4c. However, GltPh and the EAATs differ in the residues that separate these helices: there are only 5 amino acid residues between TM4b and TM4c in GltPh, while there are 58 amino acid residues that form the TM4b-4c loop in GLT-1. The extra 53 amino acid residues of TM4 in GLT-1 are likely to result in their differences in spatial conformation with a conformational shift that increases the proximity of TM2 and TM4 in the inward-facing conformation of the transporter.

The difference in the inhibitory effect by CuPh on transport activity could potentially be explained by changes in aqueous accessibility of individual cysteines. To assess this possibility, we treated the cells with MTSET, a membrane-impermeable sulfhydryl reagent that can interact with individual cysteines and form a disulfide bond that locks the transporter structure. I93C and I97C were not sensitive to MTSET. However, MTSET resulted in a dose-dependent reduction in substrate uptake of V241C (Fig. 7A). To detect changes in the aqueous accessibility of the single cysteine mutants, we added various external media. The inhibition of transport activity by MTSET did not differ for I93C and I97C in inward or outward-facing conformations (Fig. 7B,C). However, MTSET-mediated inhibition of transport activity by V241C was decreased in both the inward-facing and outward-facing states of the transporter (Fig. 7D). These experiments suggest that Val-241 is less accessible to the extracellular medium in the inward-facing and outward-facing state of transporter because of the conformational shift, which rules out a change in aqueous access as an explanation for the enhanced effects of applying CuPh in the presence of glutamate or potassium. Therefore, we infer that the inward-facing conformation leads to close spacing between TM2 and TM4 residues and that this shift in spacing is facilitated by the TM4b-c loop.

Though few research reports have focused on the TM4b-4c loop in EAATs, evidence supports the possibility that it has integral effects on EAAT activity. The TM4b-4c loop in GLT-1 has been demonstrated to contain a conformation-dependent trypsin cleavage site, suggesting that large conformational changes occur in this segment during substrate transport. Furthermore, the TM4b-4c loop has been demonstrated to be exposed to extracellular solution. The TM4b-4c loop extends from the center to the periphery of the transporter, and then back to the center. In contrast to our findings, the results of fluorescence resonance energy transfer (FRET) suggest that there are no large conformational changes of the TM4b-4c loop during the transport cycle. However, FRET reflects only the mean values of protein data in various transport states and therefore cannot indicate complex conformational changes. Using single molecule FRET to observe the motion of GltPh monomers, the conformational shift was shown to be random and independent. A recent study has shown that anions can conduct conversion of transporters to an "outside" state by opening channels as a branching reaction from intermediate conformations. The lateral movement of transporter domains can promote instantaneous EAAT/GltPh anion channel opening. Our studies showed that large changes occur for the distances between I93C (TM2) and V241C (TM4) or I97C (TM2) and V241C (TM4) during the transport cycle. Because the spatial position of TM2 remains unchanged during substrate uptake, large changes are likely to occur in the conformation of the TM4b-4c loop. The TM4b-4c loop may move inward with the transport core relative to the rest of the transporter, or it may rotate toward Ile-93 and Ile-97 in the inward-facing conformation of the transporter. Previous research showed that translocation of the fully loaded and occluded transport domain was affected by excision of the 3L4 loop. According to our results, we suggest that the translocation failure of the transport core was due to the impaired inward-facing movement of TM4, which was caused by the removal of the 3L4 loop. In the outward-facing conformation of the transporter, which is induced by TBOA, the opening of HP2 causes no movement of the TM4b-4c loop. Furthermore, the TM4b-4c loop may have an effect on substrate transport in eukaryotic glutamate transporters. The TM4b-4c loop may play an importantly assistive role in the conformational changes of the transport channel because it can greatly support the conformational shift of HP1, HP2 and TM7 and promote substrate release into the cell. At the same time, specific amino acid residues of the TM4b-4c loop may be involved in the constitution of the transport channel. These hypotheses warrant further research.

Materials and Methods

Generation and subcloning of mutants. Site-directed mutagenesis was performed as previously described using DNA encoding a cysteine-less GLT-1 (CL-GLT-1) (from rats) as a template. Escherichia coli CJ236 (dut , ung ) was used for transformation. A single-stranded DNA molecule containing uridine was produced according to the experimental protocol from Stratagene with helper phage R408. Mutagenic antisense primers were used to introduce the mutations. The mutant segments were subcloned into the CL-GLT-1 sequence in the vector pBlueScript SK (-) using the restriction enzymes EcoRI and AvrII or AvrII and XhoI. Finally, the mutagenesis and cloning of the constructs were confirmed by sequencing.

Cell growth and expression. HeLa cells were purchased from ATCC (Manassas, VA, USA) and cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal calf serum, 200 U/ml penicillin, 200 μg/ml streptomycin, and 2 mM glutamine. Confluent HeLa cells in 24-well plates were infected with recombinant vaccinia/T7 virus vTF using 150 μL of virus in serum-free Dulbecco’s Modified Eagle’s Medium as previously described. After 30 min incubation, the CL-GLT-1 or mutant constructs were transfected into HeLa cells using 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cells were incubated at 37 °C for 16–20 h prior to the transport assay.

Transport assay. The uptake of d-[3H]-aspartic acid was measured after 16–20 h transfection. The wells were washed once with choline chloride (ChCl) solution (150 mM ChCl, 5 mM KPi, pH 7.4, 0.5 mM MgSO4, and
0.3 mM CaCl₂) and then incubated with NaCl solution (150 mM NaCl, 5 mM KPi, pH 7.4, 0.5 mM MgSO₄, and 0.3 mM CaCl₂) supplemented with 0.4 μCi (0.15 μM) d-[³H]-aspartate for 10 min. Ice-cold NaCl solution was added to stop substrate uptake, and the cells were lysed with 1% sodium dodecyl sulfate. Finally, radiolabeled aspartic acid in the HeLa cells was assayed by liquid scintillation counting. All uptake data were presented after subtracting the values obtained in cells transfected with the vector pBluescript SK (-).

**Cell surface Biotinylation.** HeLa cells were plated onto 6-cm plates and after 24 hours cells were transfected with the CL-GLT-1 or mutant constructs. HeLa cell surface expression levels of CL-GLT-1 and the mutants were tested using the membrane-impermeable biotinylation reagent EZ-Link™ Sulfo-NHS-SS-Biotin (Thermo Scientific, #21331). HeLa cells in 6-cm plates were washed twice with ice-cold PBS (pH 8.0) after 16–20 hours transfection and then incubated with 2.5 ml of EZ-Link™ Sulfo-NHS-SS-Biotin (0.5 mg/ml in PBS) in two successive 20 minute incubations on ice with gentle shaking. The cells were washed twice with 100 mM glycine to removed non-reacted biotinylation reagent by incubation on ice for 20 min. The cells were lysed on ice for 20 min in 750 μl of cell lysis buffer. The cell debris was removed by centrifugation at 12,000 × g for 20 minutes at 4 °C. Supernatants (the total proteins) were transferred to new tubes and 200 μl of streptavidin-agarose beads were added in order to bind the biotin-labeled cell membrane proteins. Centrifugation for 1 min at 4 °C and supernatants (the non-biotinylated proteins) were transferred to new tubes, then washing three times with ice cold lysis buffer. At last washing once with ice cold PBS and centrifugation for 1 min at 4 °C. The lower were the member protein samples (the biotinylated proteins) and the total proteins, non-biotinylated proteins were used for western blot.

**Western blot analysis.** Samples were boiled at 55 °C for 30 min with protein loading buffer. Protein samples were fractionated by 10% SDS-PAGE, and then proteins were transferred onto polyvinylidene difluoride membranes. After blocking with 5% BSA for 1.5 h at room temperature, the membranes were incubated overnight at 4 °C with an anti-GLT-1 antibody. Integrin was used as an internal control. The membranes were washed three times with TBST and incubated with secondary antibodies for 1 h at room temperature. The different bands of protein were visualized with enhanced chemiluminescence by an imaging system. We converted the western blotting bands to the gray value using the software Image J.

**Inhibition of transport by CuPh.** Each well was washed once with ChCl solution. Then cells were incubated with different concentrations of CuPh for 5 min at room temperature. After 5 min, the medium was sequentially removed, and the cells were washed twice with the ChCl solution followed by the detection of transporter-mediated d-[³H]-aspartic acid uptake. CuPh stock solution was prepared by mixing 0.4 ml of 1.25 M 1,10-phenanthroline in water:ethanol (1:1) and 0.6 ml of 250 mM CuSO₄. Each experiment was performed at least three times.

**Restoration of activity with dithiothreitol.** Each well was washed once with ChCl solution. Then the cells were incubated with CuPh at the indicated concentrations for 5 min at room temperature. After 5 min, the medium was sequentially removed, and the cells were washed twice with the ChCl solution. Cells were preincubated with 20 mM dithiothreitol (DTT) for 5 min at room temperature, and subsequently were washed again with ChCl solution followed by the detection of transporter-mediated d-[³H]-aspartate uptake. Each experiment was performed at least three times.

**Inhibition of transport by Cd²⁺.** Each well was washed once with choline solution. Then cells were incubated with 500 μM cadmium chloride in NaCl solution with d-[³H]-aspartic acid for 10 min at room temperature. After 10 min, the transport medium was removed sequentially, and the cells were washed twice with cold NaCl solution. Finally, cells were lysed with SDS followed by scintillation counting.

**Kinetics assay.** Cells were incubated with 154 nM d-[³H]-aspartic acid combined with unlabeled d-aspartate at final concentrations of 1, 3, 10, 50, 100, 500, 1000, and 1500 μM for 10 min at room temperature after pretreatment in the absence or presence of CuPh at indicated concentrations. The Kₘ and Vₘₐₓ values were measured with the Hill equation by using non-linear fitting in Origin 7.5 software (Northampton, MA, USA). The Vₘₐₓ was expressed as a percentage of the Vₘₐₓ of CL-GLT-1 without CuPh treatment. Each experiment was performed at least three times.

**Effects of external media on oxidative inhibition by CuPh or sulfhydryl reagent.** Each well was washed once with ChCl solution. Then cells were incubated with media of different compositions with or without the indicated concentrations of CuPh or MTSET for 5 min at room temperature. The preincubation media contained one of the following: NaCl, NaCl + 1 mM l-glutamate, NaCl + 20 μM d-l-threo-β-benzyloxyaspartate (TBOA), KCl (150 mM KCl, 5 mM KPi, pH 7.4, 0.5 mM MgSO₄, and 0.3 mM CaCl₂), ChCl, or LiCl (150 mM LiCl, 5 mM KPi, pH 7.4, 0.5 mM MgSO₄, and 0.3 mM CaCl₂). After 5 min, the medium was sequentially removed, and the cells were washed twice with the ChCl solution followed by the detection of transporter-mediated d-[³H]-aspartate uptake. Each experiment was performed at least three times.
Statistical analysis. All the data are presented as means ± SE from three independent experiments. One-way ANOVA with post-hoc multiple comparison or the Student’s t test was used to accomplish the statistical analyses with SPSS 16.0 statistical software. Differences were considered significant at P < 0.05 or P < 0.01.

References
1. Arriza, J. L. et al. G. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 14, 5559–5569 (1994).
2. Arriza, J. L., Eliasof, S., Kavanaugh, M. P. & Amara, S. G. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci USA 94, 4155–4160 (1997).
3. Fairman, W. et al. An excitatory amino acid transporter with properties of a ligand-gated chloride channel. Nature 375, 599–603 (1995).
4. Kanai, Y. & Hediger, M. A. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 360, 467–471 (1992).
5. Pines, G. et al. Cloning and expression of a rat brain L-glutamate transporter. Nature 360, 464–467 (1992).
6. Storck, T., Schulte, S., Hofmann, K. & Stoffel, W. Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci USA 89, 10955–10959 (1992).
7. Slotboom, D. J. et al. A conserved serine-rich stretch in the glutamate transporter family forms a substrate-sensitive reentrant loop. Proc Natl Acad Sci USA 96, 14282–14287 (1999).
8. Brocke, L., Bendahan, A., Grunewald, M. & Kanner, B. I. Proximity of two oppositely oriented re-entrant loops in the glutamate transporter GLT-1 identified by paired cysteine mutagenesis. J Biol Chem 277, 3985–3992 (2002).
9. Boudker, O. et al. Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. Nature 445, 387–393 (2007).
10. Crisman, T. J., Qu, S., Kanner, B. I. & Forrest, L. R. Inward-facing conformation of glutamate transporters as revealed by their inverted-topology structural repeats. Proc Natl Acad Sci USA 106, 20752–20757 (2009).
11. Grewer, C. et al. Individual subunits of the glutamate transporter EAAC1 homotrimer function independently of each other. Biochemistry 44, 11913–11923 (2005).
12. Grunewald, M. & Kanner, B. I. The accessibility of a novel reentrant loop of the glutamate transporter GLT-1 is restricted by its substrate. J Biol Chem 275, 9684–9698 (2000).
13. Grunewald, M. & Menaker, D. & Kanner, B. I. Cysteine-scanning Mutagenesis Reveals a Conformationally Sensitive Reentrant Pore-Loop in the Glutamate Transporter GLT-1. J Biol Chem 277, 26074–26080 (2002).
14. Leighton, B. H. et al. Structural rearrangements at the translocation pore of the human glutamate transporter, EAAT1. J Biol Chem 281, 29788–29796 (2006).
15. Qu, S. & Kanner, B. I. Substrates and non-transportable analogues induce structural rearrangements at the extracellular entrance of the glnal glutamate transporter GLT-1/EAAT2. J Biol Chem 283, 26391–26400 (2008).
16. Reyes, N., Ginter, C. & Boudker, O. Transport mechanism of a bacterial homologue of glutamate transporters. Nature 462, 880–885 (2009).
17. Shrivastava, I. H., Jiang, J., Amara, S. G. & Bahar, I. Time-resolved mechanism of extracellular gate opening and substrate binding in a glutamate transporter. J Biol Chem 283, 28680–28690 (2008).
18. Slotboom, D. J., Konings, W. N. & Lolkema, J. S. Structural features of the glutamate transporter family. Microbiol Mol Biol Rev 63, 293–307 (1999).
19. Teichman, S., Qu, S. & Kanner, B. I. The equivalent of a thallium binding residue from an archeal homolog controls cation interactions in brain glutamate transporters. Proc Natl Acad Sci USA 106, 14297–302 (2009).
20. Yernool, D., Boudker, O., Jin, Y. & Gouaux, E. Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature 431, 811–818 (2004).
21. Grewer, C. et al. Glutamate forward and reverse transport: From molecular mechanism to transporter-mediated release after ischemia. IUBMB Life 60, 609–619 (2008).
22. Rose, E. M. et al. Glutamate transporter coupling to Na+, K+-ATPase. J Neurosci 29, 8143–8155 (2009).
23. Verdon, G. & Boudker, O. Crystal structure of an asymmetric trimer of a bacterial glutamate transporter homolog. Nat Struct Mol Biol 19, 355–357 (2012).
24. Jensen, S., Guskov, A., Rempel, S., Hanelt, I. & Slotboom, D. J. Crystal structure of a substrate-free aspartate transporter. Nat Struct Mol Biol 20, 1224–1226 (2013).
25. Verdon, G., Oh, S., Serio, R. N. & Boudker, O. Coupled ion binding and structural transitions along the transport cycle of glutamate transporters. Elife 3, e2283 (2014).
26. Huang, Z. & Takjhorshid, E. Dynamics of the extracellular gate and ion-substrate coupling in the glutamate transporter. Biophys J 95, 2292–2300 (2008).
27. Koss, X., Zomot, E., Zhang, X. & Qu, S. Investigating substrate-induced motion between the scaffold and transport domains in the glutamate transporter EAAT1. Mol Pharmacol 86, 657–664 (2014).
28. Zomot, E., Zhou, Y. & Kanner, B. I. Proximity of transmembrane domains 1 and 3 of the gamma-aminobutyric acid transporter GAT-1 inferred from paired cysteine mutagenesis. J Biol Chem 280, 25512–25516 (2005).
29. Perez-Garcia, M. T., Chiamvimonvat, N., Marban, E. & Tomasselli, G. F. Structure of the sodium channel pore revealed by serial cysteine mutagenesis. Proc Natl Acad Sci USA 93, 300–304 (1996).
30. Benitah, J. P., Tomasselli, G. F. & Marban, E. Adjacent pore-lining residues within sodium channels identified by paired cysteine mutagenesis. Proc Natl Acad Sci USA 93, 7392–7396 (1996).
31. Shlaifer, I. & Kanner, B. I. Conformationally sensitive reactivity to permeant sulfhydryl reagents of cysteine residues engineered into helical hairpin 1 of the glutamate transporter GLT-1. Mol Pharmacol 71, 1341–1348 (2007).
32. Kawarabayashi, Y. et al. Complete sequence and gene organization of the genome of a hyper-thermophilic archaeabacterium, Pyrococcus horikoshii OT3. DNA Res. 5, 147–155 (1998).
33. Grunewald, M. & Kanner, B. I. Conformational changes monitored on the glutamate transporter GLT-1 indicate the existence of two neurotransmitter-bound states. J Biol Chem 270, 17017–17024 (1995).
34. Grunewald, M., Bendahan, A. & Kanner, B. I. Biotinylation of single cysteine mutants of the glutamate transporter GLT-1 from rat brain reveals its unusual topology. Neuron 21, 623–632 (1998).
35. Seal, R. P., Leighton, B. H. & Amara, S. G. A model for the topology of excitatory amino acid transporters determined by the extracellular accessibility of substituted cysteines. Neuron 25, 695–706 (2000).
36. Koch, H. P. & Larsson, H. P. Small-scale molecular motions accomplish glutamate uptake in human glutamate transporters. J Neurosci 25, 1730–1736 (2005).
37. Erkens, G. B., Hanelt, I., Goudsmit, J. M. & Slotboom, D. J. Unsynchronised subunit motion in single trimeric sodium-coupled aspartate transporters. Nature 502, 119–123 (2013).
38. Machteins, J. P., Kortzak, D. & Lansche, C. Mechanisms of anion conduction by coupled glutamate transporters. Cell 160, 542–553 (2015).
39. Mulligan, C. & Mindell, J. A. Mechanism of Transport Modulation by an Extracellular Loop in an Archaeal Excitatory Amino Acid Transporter (EAAT) Homolog. J Biol Chem 288, 35266–35276 (2013).
40. Kleinberger-Doron, N. & Kanner, B. I. Identification of tryptophan residues critical for the function and targeting of the gamma-aminobutyric acid transporter (subtype A). J Biol Chem 269, 3063–3067 (1994).
41. Kunkel, T. A., Roberts, J. D. & Zakour, R. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 154, 367–382 (1987).
42. Fuerst, T. R., Niles, E. G., Studier, F. W. & Moss, B. Eukaryotic transient expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 83, 8122–8126 (1986).
43. Hussainzada, N., Banerjee, A. & Swaan, P. W. Transmembrane domain VII of the human apical sodium-dependent bile acid transporter ASBT (SLC10A2) lines the substrate translocation pathway. Mol Pharmacol 70, 1565–1574 (2006).
44. Hussainzada, N., Khandewal, A. & Swaan, P. W. Conformational flexibility of helix VI is essential for substrate permeation of the human apical sodium-dependent bile acid transporter. Mol Pharmacol 73, 305–13 (2008).

Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (Grant 31170734, 31570716), the Science and Technology Planning Project of Guangdong Province (2012B050200003, 2013B021800305, 2016A050502025), the Science and Technology Planning Project of Guangzhou (20134500018, 20144100008), the Scientific and Technological Innovation Programs of Higher Education Institution in Guangdong (2013KJCX0041) and the International Centre for Genetic Engineering and Biotechnology (Grant CRP/CHN11-01).

Author Contributions
S.Q. and X.Z. designed the research; X.R., F.T., X.W., X.Z. and L.L. performed the experiments; S.Q., F.T. and X.Z. analyzed the data; and S.Q., X.R. and X.W. wrote the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Rong, X. et al. TM4 of the glutamate transporter GLT-1 experiences substrate-induced motion during the transport cycle. Sci. Rep. 6, 34522; doi: 10.1038/srep34522 (2016).

© The Author(s) 2016